BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37933638)

  • 1. The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
    Fatima N; Best OG; Belov L; Christopherson RI
    Leuk Lymphoma; 2024 Feb; 65(2):242-249. PubMed ID: 37933638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenylated proteins in mouse B16-F10 melanoma cells cluster in functional categories: a new paradigm for cellular regulation?
    Fatima N; Alomari M; Belov L; Shen Y; Christopherson RI
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):255-263. PubMed ID: 34738868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the Detailed AMPylated Reaction Mechanism for the Huntingtin Yeast-Interacting Protein E Enzyme HYPE.
    Liu M; Huai Z; Tan H; Chen G
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and validation of a novel inhibitor of HYPE-mediated AMPylation.
    Camara A; Chugh H; George A; Dolidze L; Ryu K; Holly KJ; Flaherty DP; Mattoo S
    Cell Stress Chaperones; 2024 Jun; 29(3):404-424. PubMed ID: 38599565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
    Christopherson RI; Mactier S; Almazi JG; Kohnke PL; Best OG; Mulligan SP
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):375-83. PubMed ID: 24940695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfolded protein response-regulated Drosophila Fic (dFic) protein reversibly AMPylates BiP chaperone during endoplasmic reticulum homeostasis.
    Ham H; Woolery AR; Tracy C; Stenesen D; Krämer H; Orth K
    J Biol Chem; 2014 Dec; 289(52):36059-69. PubMed ID: 25395623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
    Wang P; Pavletic ZS; Joshi SS
    Leuk Lymphoma; 2002 Sep; 43(9):1827-35. PubMed ID: 12685840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Profiling of Huntingtin-associated protein E (HYPE)-Mediated AMPylation through a Chemical Proteomic Approach.
    Broncel M; Serwa RA; Bunney TD; Katan M; Tate EW
    Mol Cell Proteomics; 2016 Feb; 15(2):715-25. PubMed ID: 26604261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
    Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
    Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HypE-specific nanobodies as tools to modulate HypE-mediated target AMPylation.
    Truttmann MC; Wu Q; Stiegeler S; Duarte JN; Ingram J; Ploegh HL
    J Biol Chem; 2015 Apr; 290(14):9087-100. PubMed ID: 25678711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease.
    Sanyal A; Dutta S; Camara A; Chandran A; Koller A; Watson BG; Sengupta R; Ysselstein D; Montenegro P; Cannon J; Rochet JC; Mattoo S
    J Mol Biol; 2019 May; 431(12):2266-2282. PubMed ID: 31034889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
    Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
    Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
    Robertson LE; Denny AW; Huh YO; Plunkett W; Keating MJ; Nelson JA
    Cancer Chemother Pharmacol; 1996; 37(5):445-50. PubMed ID: 8599867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Crassini K; Stevenson WS; Mulligan SP; Best OG
    Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.